Press Release: Butterfly Network to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

Dow Jones
02/03
BURLINGTON, Mass. & NEW YORK--(BUSINESS WIRE)--February 03, 2026-- 

Butterfly Network, Inc. (NYSE: BFLY) ("Butterfly"), a digital health company transforming care with portable, semiconductor-based ultrasound technology and intuitive software, announced that it will report fourth quarter and full year 2025 financial results on Thursday, February 26, 2026, at 8:00 am ET.

Joseph DeVivo, President, Chief Executive Officer and Chairman of the Board, and John Doherty, Executive Vice President and Chief Financial Officer, will host a conference call and webcast before the market opens on February 26 to discuss the financial performance and operational progress.

The conference call will be broadcast live in listen-only mode via a webcast on Butterfly's Investor Relations website at Events & Presentations.

Individuals interested in listening to the conference call on your telephone may do so by dialing approximately ten minutes prior to start time:

United States (Local): +1 646 844 6383

United States (Toll-Free): +1 833 470 1428

Global Dial-In Numbers:https://www.netroadshow.com/events/global-numbers?confId=91551

Access Code: 965970

After the live webcast, the call will be archived on Butterfly's Investor Relations page. In addition, a telephone replay of the call will be available until March 5, 2026, by dialing:

United States (Local): +1 929 458 6194

United States (Toll-Free): +1 866 813 9403

Access Code: 270376

About Butterfly Network

Butterfly Network, Inc. (NYSE: BFLY) is a healthcare company driving a digital revolution in medical imaging with its proprietary Ultrasound-on-Chip$(TM)$ semiconductor technology and ultrasound software solutions. In 2018, Butterfly launched the world's first handheld, single-probe, whole-body ultrasound system, Butterfly iQ. The iQ+ followed in 2020, and the iQ3 in 2024, each with improved processing power and performance by leveraging Moore's Law. The iQ3 earned Best Medical Technology at the 2024 Prix Galien USA Awards, a prestigious honor and one of the highest accolades in healthcare. Butterfly's innovations have also been recognized by Fierce 50, TIME's Best Inventions and Fast Company's World Changing Ideas, among other achievements.

Butterfly combines advanced hardware, intelligent software, AI, services, and education to drive adoption of affordable, accessible imaging. Clinical publications demonstrate that its handheld ultrasound probes paired with Compass(TM) enterprise workflow software, can help hospital systems improve care workflows, reduce costs, and enhance provider economics. With a cloud-based solution that enables care anywhere through next-generation mobility, Butterfly aims to democratize healthcare by addressing critical global healthcare challenges. Butterfly devices are commercially available to trained healthcare practitioners in areas including, but not limited to, parts of Africa, Asia, Australia, Europe, the Middle East, North America and South America; to learn more about available countries, visit: https://www.butterflynetwork.com/choose-your-country.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260203569465/en/

 
    CONTACT:    Investors: 

John Doherty

Chief Financial Officer, Butterfly

investors@butterflynetinc.com

or

Steve Halper

LifeSci Advisors (IR Representative)

646-876-6455

shalper@lifesciadvisors.com

 
 

(END) Dow Jones Newswires

February 03, 2026 08:02 ET (13:02 GMT)

應版權方要求,你需要登入查看該內容

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10